Navigation Links
Cellectis bioresearch Makes Genome Engineering Affordable for All Users
Date:2/28/2011

PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access™, the first fee-for-service custom TALEN(1).

Recognized as a pioneer in the development of innovative research products for genome customization, Cellectis bioresearch brings today the life sciences community a new tool for specifically modifying genes in any type of cell.

The service will start with the TALEN Access™ offer, which provides a pair of TALENs for 5,000 euro/US$, delivered in less than 3 weeks.

"What we are offering here is a true commercial revolution," said Luc Selig, VP Sales and Marketing at Cellectis bioresearch. "We are keeping our promise to make genome customization affordable for the hundred of thousands academic research labs."

For further information or to place orders, please go to www.cellectis-bioresearch.com/talen.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com.

Follow Cellectis on Twitter at www.twitter.com/cellectis.  

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with the IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nuclease


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
2. Cellectis Publishes Its Financial Statement for the First Half of 2010
3. Cellectis bioresearch Announces Establishment of Subsidiary in the US
4. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
5. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
6. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
7. SAP Makes Life Easier for Patients and More Efficient for Healthcare Providers Through New Technology
8. Pinnaclife Makes it Official With Launch Slated for March 1st
9. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
10. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
11. Panasonic Makes Investment in Houston-based CardioNexus Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):